// STATE LEGISLATION TRACKER

Hawaii HB 561: RELATING TO PHARMACISTS.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: In committee

State: Hawaii
Bill: HB 561
Session: 2026
Filed: 2025-01-17
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

HB561 is a narrow telepharmacy bill for medically underserved patients at facilities tied to federal 340B covered entities. Based on the title, subjects, and available text, it does not directly change peptide compounding, off-label prescribing, NP or naturopath scope, controlled substances, or prescription monitoring.

Key Points

May make pharmacy access easier at certain 340B clinics or facilities
Does not create a new peptide prescribing pathway
Does not appear to expand 503A or 503B peptide compounding authority
No clear change to NP, naturopath, or telehealth prescriber scope
Remote pharmacist oversight is limited to specific covered-entity settings

What to Watch For

✓

Opportunity Could improve medication access for patients using eligible underserved-area clinics.

Note Peptide relevance is indirect unless a patient fills prescriptions through a covered 340B facility.

Concern Because the bill is narrow, it likely will not help patients seeking compounded peptide access.

Where the Bill Stands

The bill was introduced, referred to House committees, and carried over to the 2026 regular session.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws